Cargando…

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

BACKGROUND: Elderly patients with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients, and the optimal treatment strategy for this group remains controversial. We conducted a retrospective analysis to investigate the clinical features and outcomes of elderly patients (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Peng, Han, Ying, Jiang, Shi-Yu, He, Xiao-Hui, Qin, Yan, Gui, Lin, Zhou, Sheng-Yu, Zhou, Li-Qiang, Yang, Jian- Liang, Yang, Sheng, Wen, Ting-Yu, Shi, Yuan-Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759121/ https://www.ncbi.nlm.nih.gov/pubmed/31335477 http://dx.doi.org/10.1097/CM9.0000000000000354

Ejemplares similares

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
por: Wang, Xiaoyan, et al.
Publicado: (2023)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
por: Huang, Yu, et al.
Publicado: (2017)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
por: Chen, Haizhu, et al.
Publicado: (2022)

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
por: Nair, Reena, et al.
Publicado: (2023)

Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era
por: Wang, Qin, et al.
Publicado: (2016)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Outcomes of diffuse large B-cell lymphoma in elderly patients—real-world experience from a middle-income country setting
por: Sarker, Chandrayee, et al.
Publicado: (2021)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma
por: Nowakowski, Grzegorz, et al.
Publicado: (2022)

Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
por: Liang, Xiao-jie, et al.
Publicado: (2022)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
por: Wang, Shuo, et al.
Publicado: (2021)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients
por: Zhou, Minghan, et al.
Publicado: (2022)

Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients
por: Xu, Yi, et al.
Publicado: (2023)

R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma
por: He, Xiao-Hui, et al.
Publicado: (2012)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Primary appendiceal diffuse large B-cell lymphoma initially presenting as acute appendicitis: A case report
por: Liu, Kai-Yuan, et al.
Publicado: (2022)

Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010–2015
por: Huang, Huai-Hsuan, et al.
Publicado: (2020)

A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma
por: Zhou, Hao, et al.
Publicado: (2020)

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis
por: Song, Chen-Ge, et al.
Publicado: (2015)

Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies
por: Xu, Peng-peng, et al.
Publicado: (2018)

Oral Chemotherapy Application in Elderly Patients With Diffuse Large B-Cell Lymphoma: An Alternative Regimen in Retrospective Analysis
por: Liao, Pi-Han, et al.
Publicado: (2022)

Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma
por: Zhou, Xiaonan, et al.
Publicado: (2022)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma: a retrospective study of 64 patients from a single center
por: He, Xiao-Hui, et al.
Publicado: (2012)

Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients
por: Zhou, Shujuan, et al.
Publicado: (2017)

Primary diffuse large B-cell lymphoma of the breast: A retrospective study of outcomes and insulin resistance
por: Zhou, Weiling, et al.
Publicado: (2023)

Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
por: Yang, Ping, et al.
Publicado: (2023)

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study
por: Chuang, Tzer-Ming, et al.
Publicado: (2021)

Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population
por: Nakamura, Nobuhiko, et al.
Publicado: (2023)

Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
por: Wang, Siqian, et al.
Publicado: (2018)

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
por: Shen, Rong, et al.
Publicado: (2023)

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
por: Khor, Sara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aol0d5if1mog0nl3btq8t8i4u5